https://scholars.lib.ntu.edu.tw/handle/123456789/495435
Title: | The risk of osteonecrosis of the jaws in taiwanese osteoporotic patients treated with oral alendronate or raloxifene | Authors: | WEI-YIH CHIU JUNG-YIEN CHIEN WEI-SHIUNG YANG JYH-MING JIMMY JUANG JANG-JAER LEE KEH-SUNG TSAI |
Issue Date: | 2014 | Publisher: | Endocrine Society | Journal Volume: | 99 | Journal Issue: | 8 | Start page/Pages: | 2729-2735 | Source: | Journal of Clinical Endocrinology and Metabolism | Abstract: | Background: This study aimed to explore the possible association between osteonecrosis of the jaws (ONJ) and oral alendronate or raloxifene used for osteoporosis and to estimate its absolute and attributable risks in the Taiwanese population. Methods: Using an electronic medical records system and manual confirmation of ONJ, we identified patients who began taking alendronate or raloxifene for osteoporosis and developed ONJ between January 2000 and April 2012. Results: The incidence of ONJ associated with oral alendronate for the management of osteoporosis began after 1 year of drug exposure and progressively increased with longer durations of therapy, specifically from 0.23% to 0.92% as the duration of treatment went from 2 years to 10 years. The overall frequency of ONJ related to oral alendronate over a 12-year period was 0.55%. The incidence rate of ONJ attributed to alendronate exposure was 283 per 100 000 persons per year. On multivariate Cox proportional analysis, adjusting for the potential confounders, alendronate remains an independent predictor for ONJ occurrence [hazard ratio 7.42 (1.02-54.09)] compared with raloxifene. Advanced age, drug duration, and coexisting diabetes and rheumatoid arthritis are contributing factors to the development of oral alendronate-related ONJ. Conclusion: We provided the evidence to support the association of ONJ with oral alendronate used in the treatment or prevention of osteoporosis. Copyright ? 2014 by the Endocrine Society. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84905842171&doi=10.1210%2fjc.2013-4119&partnerID=40&md5=1f57ce86169e4e5488ad44b5966eeca2 https://scholars.lib.ntu.edu.tw/handle/123456789/495435 |
ISSN: | 0021-972X | DOI: | 10.1210/jc.2013-4119 | SDG/Keyword: | Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Female; Humans; Male; Middle Aged; Osteoporosis; Raloxifene; Retrospective Studies; Risk Factors; Taiwan |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.